The $1.9 million increase in other general and administrative expenses was primarily driven by increases of $1.2 million in corporate communications expenses and $0.9 million in business travel expenses, partially offset by decreases of $0.3 million in recruiting and placement expenses and $0.2 million in rent and facilities expenses.

filing / Aug 10, 2026 / receipt

The $4.2 million increase in other general and administrative expenses was primarily driven by increases of $1.9 million in corporate communications expenses, $1.6 million in business travel expenses, $0.6 million in recruiting and placement expenses, and $0.4 million in information technology expenses.

filing / Aug 10, 2026 / receipt

Outside the United States, pharmaceutical sales are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as those we are developing or may develop in the future.

filing / Aug 10, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate meaningful revenue and achieve and sustain profitability for our lead product or commercialize our product candidates.

filing / Aug 10, 2026 / receipt

The $2.2 million increase in other general and administrative expenses was primarily driven by an increase of $0.8 million in recruiting and placement expenses, an increase of $0.7 million in business travel expenses, and an increase of $0.7 million in corporate communications expenses.

filing / May 7, 2026 / receipt

a $3.0 million increase in stock-based compensation expense, due to growth in research and development headcount, and an increase of $0.4 million in facilities and other, including a $0.2 million increase in travel expenses supporting research and development activities, due mostly to travel associated with medical conferences, offset by a decrease of $1.8 million in consulting and professional services, primarily re

filing / May 7, 2026 / receipt

Outside the United States, pharmaceutical sales are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as those we are developing or may develop in the future.

filing / May 7, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, achieve and sustain profitability or commercialize our product candidates.

filing / May 7, 2026 / receipt